Holen Sie sich die Stockscreener-App
87.39
0.65%
-0.68
Schlusskurs vom Vortag:
$88.07
Offen:
$88.09
24-Stunden-Volumen:
866.80K
Relative Volume:
0.84
Marktkapitalisierung:
$5.01B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-29.52
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
+15.62%
1M Leistung:
+0.10%
6M Leistung:
-0.13%
1J Leistung:
-33.60%
1-Tages-Spanne:
$83.46
$88.67
1-Wochen-Bereich:
$73.16
$102.80
52-Wochen-Spanne:
$73.16
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
87.37 | 5.06B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
123.88 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
99.07 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
357.36 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
89.70 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.67 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | Eingeleitet | Goldman | Buy |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Can Glaukos Corporation stock expand revenue streamsWeekly Risk Summary & Weekly Watchlist for Consistent Profits - newser.com
Backtesting results for Glaukos Corporation trading strategies2025 Market Overview & Fast Gain Swing Alerts - newser.com
Is Glaukos Corporation stock overvalued by current metrics2025 Market Outlook & Weekly High Conviction Ideas - newser.com
What risks investors should watch in Glaukos Corporation stockTake Profit & Verified Momentum Stock Ideas - newser.com
Why Glaukos Corporation stock appears on watchlists2025 Price Momentum & High Accuracy Swing Trade Signals - newser.com
Custom watchlist performance reports with Glaukos CorporationJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com
Can Glaukos Corporation (6GJ) stock double in coming years2025 Big Picture & Precise Entry and Exit Recommendations - newser.com
Glaukos Announces Participation in Upcoming Investor Conferences - The AI Journal
Zweig DiMenna Associates LLC Sells 52,200 Shares of Glaukos Corporation $GKOS - MarketBeat
Is Glaukos Corporation stock a bargain at current levelsTrade Ideas & AI Driven Stock Reports - newser.com
Will Glaukos Corporation continue its uptrendMarket Growth Report & Reliable Price Action Trade Plans - newser.com
Is Glaukos Corporation stock attractive for income investors2025 Major Catalysts & Real-Time Sentiment Analysis - newser.com
How Glaukos Corporation stock performs in stagflationMarket Performance Recap & Consistent Profit Alerts - newser.com
FY2025 Earnings Forecast for Glaukos Issued By William Blair - MarketBeat
Key metrics from Glaukos Corporation’s quarterly dataGap Up & Free Fast Entry Momentum Trade Alerts - newser.com
How Glaukos Corporation (6GJ) stock responds to job market shiftsJuly 2025 Sector Moves & Growth Focused Stock Reports - newser.com
How Glaukos Corporation stock responds to policy changesJuly 2025 Momentum & Weekly Stock Performance Updates - newser.com
Glaukos (GKOS) Is Up 17.9% After FDA Approval of Epioxa and Record Q3 Results Has the Bull Case Changed? - simplywall.st
Glaukos outlines $600M–$620M 2026 revenue outlook as Epioxa launch and iDose TR drive growth - MSN
Can Glaukos Corporation (6GJ) stock sustain free cash flow2025 Top Decliners & Safe Capital Growth Trade Ideas - newser.com
Is Glaukos Corporation stock dividend yield sustainableMarket Sentiment Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Is Glaukos Corporation stock cheap by valuation metricsTrend Reversal & Stepwise Trade Execution Plans - newser.com
Glaukos Corporation $GKOS Shares Purchased by Bessemer Group Inc. - MarketBeat
Published on: 2025-11-02 03:24:12 - newser.com
Will Glaukos Corporation (6GJ) stock remain on Wall Street radarJuly 2025 Setups & Safe Capital Growth Stock Tips - newser.com
Will Glaukos Corporation stock attract more institutional investorsJuly 2025 Sentiment & Technical Confirmation Alerts - newser.com
Will Glaukos Corporation stock keep outperforming rivals2025 Risk Factors & Safe Capital Allocation Plans - newser.com
Can Glaukos Corporation stock sustain free cash flow growth2025 Price Targets & Long Hold Capital Preservation Tips - newser.com
William Blair Issues Negative Forecast for Glaukos Earnings - MarketBeat
Why Glaukos Corporation stock remains on buy listsJuly 2025 PostEarnings & Safe Entry Trade Reports - newser.com
Glaukos Corporation $GKOS Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Why Glaukos Corporation stock appeals to dividend seekersBear Alert & Real-Time Stock Movement Alerts - newser.com
Will Glaukos Corporation stock outperform energy sector in 2025Earnings Trend Report & AI Enhanced Trading Alerts - newser.com
Published on: 2025-11-01 00:07:30 - newser.com
Glaukos Corporation (GKOS) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Glaukos Corp.’s iDose TR Study: A Potential Game-Changer in Ophthalmic Treatment - MSN
Glaukos Corporation (GKOS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Glaukos Corporation (GKOS) Stock forecasts - Yahoo! Finance UK
Glaukos Corporation (GKOS) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Here's What Key Metrics Tell Us About Glaukos (GKOS) Q3 Earnings - Yahoo Finance
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
JP Morgan Maintains Glaukos (GKOS) Overweight Recommendation - MSN
Glaukos Corporation (NYSE:GKOS) Q3 2025 Earnings Call Transcript - MSN
Glaukos (NYSE:GKOS) Sees Large Volume Increase After Earnings Beat - MarketBeat
Why Glaukos Stock Jumped Over 20% After-Hours Today - MSN
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.12%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):